Intranasal treatment with luteinising hormone releasing hormone agonist in women with endometriosis

An agonist analogue of luteinising hormone releasing hormone (buserelin) was successfully used to treat women with endometriosis. A dose of 200 micrograms administered intranasally thrice daily was found to be effective in five patients, in whom the endometriotic lesions resolved after six months' treatment. Failure occurred in a sixth patient, who received only 400 micrograms once daily. Anovulation was induced in all subjects together with suppression of menstruation after the first month of treatment. Symptoms of abdominal pain, dysmenorrhoea, and dyspareunia were relieved during treatment, and one previously infertile patient conceived within two months of stopping treatment. No side effects were reported with this dosage, and the results suggest a new form of treatment for patients with endometriosis.     

Induction of ovulation with pulsatile luteinising hormone releasing hormone

Ovulation was successfully induced with luteinising hormone releasing hormone in 28 women with hypothalamic amenorrhoea who had failed to respond to treatment with clomiphene. Luteinising hormone releasing hormone was administered in a pulsatile manner with miniaturised automatic infusion systems. The rate of ovarian follicular maturation, as monitored by serial pelvic ultrasonography, was similar to that observed in spontaneous cycles. Endocrine assessment by serial measurement of gonadotrophin, oestradiol, and progesterone concentrations showed hormone concentrations to be within the normal range. Intravenous treatment was required in only two patients, the remainder responding satisfactorily to subcutaneous infusion. All patients conceived within six cycles of treatment, and only one multiple pregnancy occurred.     

Long term treatment with luteinising hormone releasing hormone agonists and maintenance of serum testosterone to castration concentrations

Serum concentrations of luteinising hormone and testosterone were measured by radioimmunoassay one, two, four, seven, and 24 hours after the subcutaneous administration of 500 micrograms of the luteinising hormone releasing hormone agonist [D-Trp6, des-Gly-NH2(10)] LHRH ethylamide or [D-Ser(TBU)6, des-Gly-NH2(10)]LHRH ethylamide in patients who had previously received daily treatment with these peptides for 0, 1, 6, 12, 18, and 24 months. No increase in the serum concentrations of luteinising hormone or testosterone were detected at any time between one and 24 months' treatment. The data show that daily subcutaneous administration of the two luteinising hormone releasing hormone agonists used at the appropriate dose can maintain concentrations of serum androgens equivalent to those after castration during long term treatment.     

国产促性腺激素释放激素激动剂在体外受精-胚胎移植技术中的应用

目的:探讨国产促性腺激素释放激素激动剂在体外受精胚胎移植技术(invitrofertilization_embryotransfer,IVFET)中的应用。方法:选2000年8月～2001年8月我院门诊不孕症患者58例,采用IVF治疗58个周期,45个周期采用达必佳(Decapeptyl)长方案降调节,13个周期采用阿拉瑞林(Alarilin)长方案降调节,进行超促排卵。结果:58个周期共获卵675个,每周期获卵数目为11.64±2.27个,受精率72.60%,卵裂率82.86%,临床妊娠24例,临床妊娠率为41.38%。达必佳组与阿拉瑞林组,促性腺激素(Gn)用量、受精率、卵裂率、妊娠率,无显著性差异。结论:国产药物促性腺激素释放激素激动剂阿拉瑞林在IVF超促排卵中,起到了很好的降调节作用,具有临床推广应用的价值。     

Advanced carcinoma of the prostate: treatment with a gonadotrophin releasing hormone agonist

Ten patients with advanced progressive adenocarcinoma of the prostate were treated with a long acting analogue of gonadotrophin releasing hormone. Eight of these patients responded to treatment in terms of pain relief and clinical regression of tumour. Serum gonadotrophin and testosterone concentrations were significantly suppressed by the end of the second week of treatment, testosterone concentrations being comparable with those achieved by castration. The two patients who failed to respond had both relapsed previously when receiving conventional treatment, and neither showed any endocrine response to the analogue. Superagonists of gonadotrophin releasing hormone may be the treatment of choice in adenocarcinoma of the prostate, but further trials are required to establish long term safety and efficacy.     

促性腺激素释放激素激动剂联合高强度聚焦超声治疗子宫腺肌病疗效观察

目的探讨促性腺激素释放激素激动剂(GnRH-a)联合高强度聚焦超声(HIFU)治疗子宫腺肌病的临床效果。方法选择2014年1月至2016年1月在新乡市第四人民医院住院治疗的102例子宫腺肌病患者,采用GnRH-a治疗3个疗程后,应用HIFU治疗,观察治疗前1个月及治疗6个月后患者的月经周期、月经期、月经量评分、痛经视觉模拟评分(VAS)、肌瘤大小和血红蛋白水平变化。结果 102例患者治疗6个月后的月经周期、月经期与治疗前1个月比较差异均无统计学意义(t=0.312、0.461,P>0.05);治疗6个月后患者的月经量评分、痛经VAS评分和肌瘤直径均显著小于治疗前1个月(t=3.817、5.263、7.036,P<0.05);治疗6个月后患者的平均血红蛋白水平显著高于治疗前1个月(t=6.201,P<0.05)。结论 GnRH-a联合HIFU治疗子宫腺肌病能有效减轻患者的痛经、贫血等,有效控制病情,提高患者的生活质量。     

CRH刺激大鼠下丘脑脑片CRH及CRH1R的表达研究

目的　通过CRH刺激大鼠下丘脑脑片 ,探讨下丘脑CRH和CRH1R在下丘脑中的分布和表达规律。方法　采用大鼠下丘脑脑片实验模型 ,运用免疫组织化学技术 ,观察CRH刺激大鼠下丘脑脑片后CRH和CRH1R在下丘脑中的分布和表达规律。结果　CRH刺激下丘脑脑片后下丘脑CRH和CRHlR含量明显增多 ,而CP 15 45 2 6、H89可显著抑制CRH和CRHlR的增加。结论　CRH刺激下丘脑脑片后增多的CRH与CRHlR结合后进一步引起下丘脑神经元CRH和CRHlR表达增加。提示在严重创伤应激反应中 ,CRH通过PKA途径实现对下丘脑神经元CRH的表达的超短正反馈调节。     

促性腺激素释放激素激动剂延长给药间隔治疗子宫腺肌病和子宫内膜异位症的疗效

目的探讨促性腺激素释放激素激动剂(GnRH-a)延长给药间隔周期治疗子宫腺肌病、子宫内膜异位症(内异症)的疗效。方法子宫腺肌病、内异症患者共60例,随机分成两组(n=30)。按药方传统给药方法,每4周肌肉注射曲普瑞林3.75mg,共6次,疗程均为24周,设为对照组;以延长给药间隔周期的新方案作为研究组,每6周肌肉注射曲普瑞林3.75mg,共4次,疗程亦为24周,但总用药量减少两次。观察治疗前后痛经程度、子宫体积、血清性激素水平的变化。结果治疗结束时,两组痛经缓解率均为100%;研究组与对照组子宫体积平均缩小分别为37.6%与39.2%。两组患者药物治疗前后黄体生成素(LH)、卵泡刺激素(FSH)及雌二醇(E2)水平均明显降低(P<0.001),E2降至绝经期水平,分别为(65.6±8.7)pmol/L和(60.0±6.3)pmol/L;用药前,第1次用药后及治疗后12周、24周,研究组与对照组相比,差异均无统计学意义(P>0.05)。结论应用GnRH-a延长给药间隔的新方案治疗子宫腺肌病、内异症,同样能达到与传统方案相同的疗效,即低雌激素状态的抑制效应,但治疗费用显著降低。     

腹腔镜下子宫中心体切除术联合促性腺激素释放激素激动剂在子宫腺肌病治疗中的应用

目的:探讨腹腔镜下子宫中心体切除术联合促性腺激素释放激素激动剂(gonadotrophin-releasing hormone agonist,GnRH-a)治疗子宫腺肌病的临床疗效。方法:选取2015年1月至2017年12月在成都大学附属医院因子宫腺肌病选择腹腔镜下子宫中心体切除术的35例患者作为研究组,随机选取同期行腹腔镜下全子宫切除术的子宫腺肌病患者35例作为对照组,其中行腹腔镜下子宫中心体切除术患者,术后给予促性腺激素释放激素激动剂(gonadotrophin-releasing hormone agonist,GnRHa)即诺雷得治疗6个月。2组患者术后均随访6～12个月,比较手术时间、术中出血、术后胃肠功能恢复时间、痛经改善情况、术后性生活质量、围绝经期症状及性激素水平及患者满意度。结果:研究组手术时间比对照组长,术中出血量比对照组多,差异有统计学意义(P=0.000),2组术后胃肠道功能恢复时间比较,差异无统计学意义(P=0.874);2组术后痛经较术前均明显减轻,差异有统计学意义(P=0.000);研究组术后月经量较术前明显减少(P=0.000),术后子宫大小较术前缩小...     

腹腔镜卵巢囊肿剥除术结合促性腺激素释放激素激动剂治疗卵巢子宫内膜异位囊肿效果观察

目的:探讨腹腔镜卵巢囊肿剥除术结合促性腺激素释放激素激动剂治疗卵巢子宫内膜异位囊肿效果。方法:选取2017年2月至2019年6月收治的112例卵巢子宫内膜异位囊肿患者,随机分为观察组和对照组,对照组给予腹腔镜卵巢囊肿剥除术治疗,观察组联合促性腺激素释放激素激动剂（GnRH-a）治疗,比较两组手术指标、临床疗效、治疗前后性激素水平、治疗后半年窦卵泡数及卵巢体积、治疗后随访1年月经及妊娠情况。结果:观察组手术时间、术后排气时间较对照组显著缩短（P<0.05）;术中出血量较对照组显著减少（P<0.05）;临床疗效总有效率为92.86%,显著高于对照组的78.57%（P<0.05）;治疗前两组性激素水平无显著性差异（P>0.05）,治疗后观察组FSH、LH、E2指标水平显著低于对照组（P<0.05）;治疗后半年两组窦卵泡数、卵巢体积无差异（P>0.05）;随访1年两组月经时间、月经周期无差异（P>0.05）;术前两组不孕症发生率无显著性差异,随访1年观察组术后妊娠率为78.26%,较对照组的38.10%显著提高（P<0.05）;妊娠间隔时间较对照组显著缩短（P<0.05）;复发率为5.36%,较对照组（17.86%）显著降低（P<0.05）。结论:腹腔镜卵巢内子宫异位囊肿剥除术联合GnRH-a治疗卵巢内子宫内膜异位囊肿可提高临床疗效,缩短手术时间,减少术中出血量,加快患者恢复,使机体性激素水平维持在较低的状态,改善患者月经情况,提高妊娠率,降低复发率。     

促性腺激素释放激素激动剂在外体外受精-胚胎移植促排卵中的应用

目的 :探讨 1.2 5 m g促性腺激素释放激素激动剂 (Gn RH - a)在体外受精 -胚胎移植控制性超排卵中的效果。方法 :研究组 76例给予 1.2 5 mg促性腺激素释放激素激动剂降调节 ,对照组 98例给予 3.75 mg促性腺激素释放激素激动剂降调节。比较两组降调节后月经第 3天血中卵泡刺激素、黄体生成激素、雌二醇激素水平、获卵数、 级和 级胚胎数、妊娠率、人绝经期促性腺素使用支数。结果 :比较两组月经第 3天激素水平、获卵数、 级和 级胚胎数、妊娠率差异均无显著性 (P>0 .0 5 ) ,人绝经期促性腺素支数研究组明显少于对照组 (P<0 .0 5 )     

GnRHa及反加雌孕激素对子宫内膜异位症患者外周血及腹腔液IL-2和IL-6分泌的影响

目的比较单用GnRHa及反加雌孕激素对子宫内膜异位症(内异症)患者外周血及腹腔液IL-2及IL-6分泌的影响。方法分离外周血单个核细胞(peripheral blood mononuclear cell,PBMC)加植物血凝素诱生培养,采用酶联免疫吸附法检测28例内异症组患者和10例正常对照组C培养液上清和腹腔液中IL-2和IL-6的水平;内异症组随机分为单用GnRHa组(A组)和反加组(B组),用药治疗3月后,比较PBMC培养上清中IL-2和IL-6的水平。结果A、B两组患者术前培养液上清和腹腔液中IL-6水平显著高于对照组C(P<0.05),IL-2/IL-6比值显著低于对照组C(P<0.05);用药治疗3个月后,A、B两组患者培养液上清IL-6分泌较术前明显下降(P<0.01),IL-2/IL-6比值较术前明显升高(P<0.05),两治疗组间差异无统计学意义。结论内异症患者培养上清液和腹腔液中IL-6的升高可能与内异症的发生有关;内异症患者Th1/Th2比例失衡使细胞免疫抑制,从而使异位内膜逃避免疫监视而广泛种植;术后单用GnRHa和反加治疗内异症均能部分逆转Th2优势,具有相似的效果。     

子宫内膜异位症术后应用不同治疗周期半剂量促性腺激素释放激素激动剂的疗效观察

探讨1．875mg促性腺激素释放激素激动剂（GnRH—a）不同治疗周期对子宫内膜异位症术后的疗效。分析2010年1月至2011年6月行保守性腹腔镜手术且手术证实为盆腔子宫内膜异位症患者108例,其中术后应用半剂量GnRH—a治疗3个月的患者57例（A组）,治疗6个月的患者51例（B组）,比较两组间的临床有效率及停药后复发率和妊娠率。A、B组的临床有效率分别为73．7％（42／57）、90．2％（46／51）,差异有统计学意义（P〈0．05）,两组的复发率分别为14．O％（8／57）、5．9％（3／51）,两组的妊娠率分别为45．0％（18／40）、4／12,差异无统计学意义（P〉0．05）。术后应用6个周期GnRH—a可提高临床有效率,降低及延迟盆腔子宫内膜异位症的复发;对于有生育要求的,可考虑减少GnRH—a的治疗周期后积极妊娠。